Vaccines and biologics.
Patients with autoimmune rheumatic diseases are more susceptible to infectious complications during the course of their disease. The introduction of biologics has been a major achievement in treating these diseases, but an increased risk of infection associated with these therapies has become evident. Some infections can be prevented by vaccination and it is clearly worthwhile considering which immunisations would be sensible and practicable for these patients. To date no formal specific recommendations for patients on biologics have been published. A search was made of Medline (via PubMed) from 1970 to January 2014 to provide results. This review aims to provide a systematic analysis of the data about vaccines and biologics and considers recommendations for vaccination in adult patients with autoimmune rheumatic diseases treated with biologics.
Immuno-mediated Systemic Diseases Unit, Medicina 4, Hospital Prof. Doutor Fernando Fonseca, EPE, IC19, Amadora, Portugal.
Isabel
I
Ferreira
Department of Medicine, Centre for Rheumatology, University College of London, London, UK.
David
D
Isenberg
D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy*; D001685:Biological Factors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009894:Opportunistic Infections / Q000150:complications / Q000517:prevention & control*; D012216:Rheumatic Diseases / Q000150:complications / Q000188:drug therapy*; D014612:Vaccines / Q000627:therapeutic use*
D001685:Biological Factors; D014612:Vaccines
biologics; vaccines